TY  - JOUR
A1  - Steinhardt, Maximilian Johannes
A1  - Zhou, Xiang
A1  - Krummenast, Franziska
A1  - Meckel, Katharina
A1  - Nickel, Katharina
A1  - Böckle, David
A1  - Messerschmidt, Janin
A1  - Knorz, Sebastian
A1  - Dierks, Alexander
A1  - Heidemeier, Anke
A1  - Lapa, Constantin
A1  - Einsele, Hermann
A1  - Rasche, Leo
A1  - Kortüm, Klaus Martin
T1  - Sequential CD38 monoclonal antibody retreatment leads to deep remission in a patient with relapsed/refractory multiple myeloma
T2  - International Journal of Immunopathology and Pharmacology
N2  - We report on a currently 76-year-old female patient with relapsed/refractory (RR) multiple myeloma (MM) treated at our institution. This patient had received six lines of therapy including tandem autologous stem cell transplant, proteasome inhibitor, immunomodulatory drugs and CD38 antibody MOR202. At the last relapse, she progressed during treatment with pomalidomide and MOR202. In an individualized therapy concept, we started a multi-agent salvage therapy with pomalidomide, bortezomib, doxorubicin, dexamethasone, and CD38 antibody daratumumab (“Pom-PAD-Dara”), which resulted in a stringent complete remission with minimal residual disease (MRD) negativity after nine cycles. So far, our patient shows a progression free survival of more than 12 months. Our case demonstrates the feasibility of successful CD38 antibody retreatment in a patient with heavily pretreated CD38 antibody resistant MM.
KW  - CD38
KW  - MOR202
KW  - daratumumab
KW  - multiple myeloma
KW  - refractory
KW  - relapse
Y1  - 2020
UR  - https://opus.bibliothek.uni-wuerzburg.de/frontdoor/index/index/docId/23623
UR  - https://nbn-resolving.org/urn:nbn:de:bvb:20-opus-236235
VL  - 34
ER  -